-

$undefined

N/A

(N/A)

Merus NASDAQ:MRUS Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity.

Location: Yalelaan 62, Utrecht, 3584 CM, Netherlands | Website: www.merus.nl | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.448B

Cash

537M

Avg Qtr Burn

-46.46M

Short % of Float

13.33%

Insider Ownership

2.04%

Institutional Own.

Qtr Updated

12/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BIZENGRI® (zenocutuzumab-zbco) Details Cancer, Solid tumor/s, Non-small cell lung carcinoma, Pancreatic cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Petosemtamab (MCLA-158) +/- Keytruda (pembrolizumab) Details Cancer, Head and neck squamous cell carcinoma Suspected Mover™ Susp. Mover™	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Petosemtamab (MCLA-158) (Lgr5 x EGFR Biclonics®) Details Solid tumor/s, Cancer, Metastatic colorectal cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Petosemtamab (MCLA-158) (Lgr5 x EGFR Biclonics®) Details Metastatic colorectal cancer, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Petosemtamab (MCLA-158) (Lgr5 x EGFR Biclonics®) in comb w/ SoC Details Solid tumor/s, Cancer, Metastatic colorectal cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MCLA-129 (EGFR x c-MET Biclonics®) + Osimertinib Details Solid tumor/s, Cancer, Non-small cell lung carcinoma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MCLA-145 (CD137 x PD-L1 Biclonics®) + Keytruda Details Cancer, Solid tumor/s	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.